Entry |
|
Name |
Tepotinib (USAN/INN) |
Formula |
C29H28N6O2
|
Exact mass |
492.2274
|
Mol weight |
492.57
|
Structure |
|
Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
Remark |
Product (DG03087): | D11073<JP/US> |
|
Efficacy |
Antineoplastic |
Target |
|
Pathway |
|
Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP2C8 [HSA: 1558]
|
Interaction |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EX Other protein kinase inhibitors
L01EX21 Tepotinib
D11717 Tepotinib (USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03087 Tepotinib
D11717 Tepotinib
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG03087 Tepotinib
D11717 Tepotinib
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03087 Tepotinib
D11717 Tepotinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
MET family
MET
D11717 Tepotinib (USAN/INN)
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11717
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03087 Tepotinib
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG03087 Tepotinib
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03087 Tepotinib
|
Other DBs |
|
KCF data |
ATOM 37
1 C8y C 12.2500 -19.6000
2 C8x C 12.2500 -18.2000
3 C8x C 13.4400 -17.5000
4 C8x C 14.7000 -18.2000
5 C8y C 14.7000 -19.6000
6 C8x C 13.4400 -20.3000
7 C3b C 11.0600 -20.3000
8 N3a N 9.8000 -21.0000
9 C8y C 15.8900 -20.3000
10 N5x N 17.0800 -19.6000
11 N4y N 18.3400 -20.3000
12 C8y C 18.3400 -21.7000
13 C8x C 17.1500 -22.4000
14 C8x C 15.8900 -21.7000
15 C1b C 19.5300 -19.6000
16 C8y C 20.7200 -20.3000
17 C8x C 21.9100 -19.6000
18 C8y C 23.1700 -20.3000
19 C8x C 23.1700 -21.7000
20 C8x C 21.9800 -22.4000
21 C8x C 20.7200 -21.7000
22 C8y C 24.3600 -19.6000
23 N5x N 24.3600 -18.2000
24 C8x C 25.6200 -17.5000
25 C8y C 26.8100 -18.2000
26 C8x C 26.8100 -19.6000
27 N5x N 25.6200 -20.3000
28 O2a O 28.0000 -17.5000
29 C1b C 29.1900 -18.2000
30 C1y C 30.3800 -17.5000
31 C1x C 30.3800 -16.1000
32 C1x C 31.6400 -15.4000
33 N1y N 32.8300 -16.1000
34 C1x C 32.8300 -17.5000
35 C1x C 31.6400 -18.2000
36 C1a C 34.0200 -15.4000
37 O5x O 19.5300 -22.4000
BOND 41
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 1 7 1
8 7 8 3
9 5 9 1
10 9 10 2
11 10 11 1
12 11 12 1
13 12 13 1
14 13 14 2
15 9 14 1
16 11 15 1
17 15 16 1
18 16 17 2
19 17 18 1
20 18 19 2
21 19 20 1
22 20 21 2
23 16 21 1
24 18 22 1
25 22 23 2
26 23 24 1
27 24 25 2
28 25 26 1
29 26 27 2
30 22 27 1
31 25 28 1
32 28 29 1
33 29 30 1
34 30 31 1
35 31 32 1
36 32 33 1
37 33 34 1
38 34 35 1
39 30 35 1
40 33 36 1
41 12 37 2
|